NCCM
SVA

Nine Chapters Capital Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Nine Chapters Capital Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-12,200
Closed -$62K – 961
2015
Q3 		$62K Buy
+12,200
New +$64.6K 0.01% 938
2015
Q2 		– Sell
-13,800
Closed -$68K – 1334
2015
Q1 		$68K Buy
+13,800
New +$68K 0.01% 920

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Nine Chapters Capital Management's SVA Position: Q4 2015 in Review

Nine Chapters Capital Management sold out of Sinovac Biotech, Ltd (SVA) in Q4 2015, closing a stake of 12,200 shares — an estimated $62K sold.

Nine Chapters Capital Management first reported a position in SVA in Q1 2015 and held it in 2 quarters. The position peaked at $68K in Q1 2015. 40 funds tracked by Wall St. Rank hold SVA as of Q4 2015.

  • Nine Chapters Capital Management reported no remaining Sinovac Biotech, Ltd position as of Q4 2015 after selling out during the quarter.
  • Nine Chapters Capital Management sold 12,200 Sinovac Biotech, Ltd shares in Q4 2015, an estimated $62K.
  • Nine Chapters Capital Management first reported a position in Sinovac Biotech, Ltd in Q1 2015 and held it in 2 quarters.
  • Nine Chapters Capital Management's Sinovac Biotech, Ltd position peaked at $68K in Q1 2015.
  • 40 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2015.

Based on Nine Chapters Capital Management's 13F filing for Q4 2015.